Sanofi profit growth beats market view on early start of vaccine sales
French drug maker Sanofi on Friday posted stronger earnings growth than analysts had expected in the third quarter, helped by earlier-than-anticipated sales of seasonal vaccines.
Sanofi Earns $5B Q3 Core Profit On Strong Dupixent And Vaccine Sales, Raises 2024 Forecast
On Friday, Sanofi SA (NASDAQ:SNY) reported a third-quarter business operating income of 4.61 billion euros ($4.99 billion), up 14.4% year-over-year and 19.9% in constant currency. The company reported third-quarter sales of 13.
Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat
Sanofi stock rose early Friday after beating third-quarter sales expectations on the back of its vaccine sales.
Sanofi earnings boosted by Beyfortus, earlier vaccine sales
Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped during the third quarter.
Sanofi Profit Lifted by Early Vaccine Sales, Dupixent Growth
Sanofi profit rose on demand for seasonal vaccines and further growth in its blockbuster skin and asthma therapy Dupixent.Most Read from BloombergRobotaxis Are No Friend of Public TransportationBooming Cambridge Exposes England’s Widening Wealth GapOman Sees an Urban Future Distinct From Dubai and Abu DhabiArgentina Drug Trafficking Hotspot Sees Murders PlungeClimate Change Is Killing Buildings in Slow MotionEarnings per share excluding some items reached €2.
Sanofi posts Q3 revenue beat as Dupixent sales jump
Sanofi (SNY) stock gains as company exceeds Q3 earnings estimates with strong vaccine and Dupixent sales, and raises its full-year earnings guidance. Read more here.
Sanofi Profit, Sales Beat Estimates
The French pharmaceutical company posted better-than-expected earnings and sales in the third quarter, boosted by earlier-than-anticipated flu and respiratory syncytial virus vaccine purchases.
Sanofi shares rise as Q3 results beat forecasts on vaccines and Beyfortus sales
Sanofi (EPA:SASY) shares rose on Friday after the pharmaceutical giant posted better-than-expected third-quarter results, buoyed by strong vaccine revenues and robust early sales of Beyfortus, its respiratory syncytial
BioPharma Dive2d
Dengue is spreading and Sanofi is pulling the US market’s only vaccine. What’s next?
As Sanofi prepares to halt U.S. marketing of its dengue vaccine in 2026, locally acquired infections in the country are ...
FiercePharma1d
Sanofi shrugs off potential RSV competition from Merck as Beyfortus grows sales 382%
On a Friday call with analysts, Sanofi execs pointed to an efficacy edge for its preventive and stressed that more ...
Medscape4d
How Effective Is the High-Dose Flu Vaccine in Older Adults?
High-dose flu vaccinations resulted in a 23% reduction in hospitalizations among people aged 65 years or older, according to ...
Sanofi beats expectations with bumper third-quarter earnings
Sanofi reported stronger-than-expected third-quarter earnings on Friday, driven by early vaccine sales and robust performance ...
Sanofi Reports Strong Q3 Growth and Raises EPS Guidance
Sanofi (SNY) has released an update. Sanofi reported a robust 15.7% growth in sales for Q3 2024, driven by strong performances in its vaccine ...
The Pharma Letter1d
Sanofi outpaces expectations in third quarter 2024
Sanofi reported Q3 2024 sales growth of 15.7%, reaching 13.4 billion euros ($14.2 billion), with EPS up 12.2% to 2.86 euros.
This Vaccine Stock Just Dropped by 20%: Should You Buy the Dip?
Vaccine maker Novavax (NASDAQ: NVAX) has had a rollercoaster of a year. In May, the company's shares soared after it ...